346440 Results

Show all   Save search   Copy query
Sort   by:  
 Page size 
MetabolomicsFetal Metabolic Stress Disrupts Immune Homeostasis and Induces Proinflammatory Responses in Human Immunodeficiency Virus Type 1- and Combination Antiretroviral Therapy-Exposed Infants
Increased morbidity and fetal growth restriction are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)–infected women treated with antiretroviral (ARV) therapy. Viruses and/or pharmacological interventions such as ARVs can induce metabolic stress, skewing the cell’s...
2018-06-06 | MTBLS449 | MetaboLights
MetabolomicsA polyamine-centric blood-based metabolite panel predictive of poor response to CAR T-cell therapy in large B cell lymphoma

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (r/r) large B-cell lymphoma (LBCL) results in durable response in only a subset of patients. MYC overexpression in LBCL tumors is associated with poor response to treatment. We tested whether a MYC-driven polyamin...

2022-10-31 | MTBLS5381 | MetaboLights
MetabolomicsSerum metabolomics identifies unique inflammatory signatures to distinguish rheumatoid arthritis responders and non-responders to TNF inhibitor therapy
Rheumatoid arthritis (RA) is an auto-immune disease which causes irreversible damage to tissue and cartilage within synovial joints. Rapid diagnosis and treatment with disease-modifying therapies is essential to reduce inflammation and prevent destruction of the joint. RA is a heterogeneous disease,...
2025-08-14 | MTBLS6213 | MetaboLights
MetabolomicsMetabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

BACKGROUND: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great cl...

2022-01-13 | MTBLS239 | MetaboLights
MetabolomicsMetabolomic Profiling of Personalized Cancer Therapy Responses in Organoid Chips

This study investigates metabolomic changes associated with personalized cancer therapy responses in patient-derived organoid chips containing a reconstructed tumor microenvironment. The dataset includes de-identified sample metadata, raw mass spectrometry files, processed metabolite abundance ma...

2026-08-06 | MTBLS15195 | MetaboLights
MetabolomicsCysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
Nephropathic cystinosis is a severe monogenic kidney disorder caused by mutations in CTNS, encoding the lysosomal transporter cystinosin, resulting in lysosomal cystine accumulation. The sole treatment, cysteamine, slows down the disease progression, but does not correct the established renal proxim...
2021-06-24 | MTBLS2538 | MetaboLights
MetabolomicsOxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolomics analyses of patients' tumours, metastasis-derived patient-derived xenografts (PDX) and isogenic cell line...
2023-06-27 | MTBLS3342 | MetaboLights
MetabolomicsSafety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models
2026-04-29 | MTBLS14408 | MetaboLights
MetabolomicsIntestinal Microbe-Metabolite Network Associated with The Efficacy of Fecal Microbiota Transplantation Therapy in Inflammatory Bowel Disease

BACKGROUND: Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a type of recurrent and incurable disease, which can lead to the loss of workability, increase cancer risk and bring serious economic burden to patients. Abnormal intestin...

2026-03-11 | MTBLS3909 | MetaboLights
MetabolomicsMethionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
Sort   by:  
 Page size